Extranodal NK/T-cell lymphoma nasal type: Efficacy of pegaspargase. Report of two patients from the United Sates and review of literature

Leukemia Research

Volumn 34, Issue 1, 2010, Pages

  Reyes Jr , Vincent Edgar ^a   Al Saleem, Tahseen ^a   Robu, Valentin G ^a   Smith, Mitchell R ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE MACROGOL; CD16 ANTIGEN; CD3 ANTIGEN; CD5 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; INTERLEUKIN 2 RECEPTOR ALPHA; LATENT MEMBRANE PROTEIN 1; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; ANAPHYLAXIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER RADIOTHERAPY; CAPILLARY LEAK SYNDROME; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; ERYTHEMA; FEMALE; HUMAN; IMMUNOPHENOTYPING; LEG ULCER; LETTER; LIVER BIOPSY; LIVER INJURY; LIVER METASTASIS; LUNG EDEMA; MALE; MULTIPLE CYCLE TREATMENT; NASAL BIOPSY; NK T CELL LYMPHOMA; NOSE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SINUS CONGESTION; SKIN LYMPHOMA;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MIDDLE AGED; POLYETHYLENE GLYCOLS;

EID: 73249121391     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.09.002     Document Type: Letter

References (33)

1. Devita V., Rosenberg S., and Hellman S. Cancer: principles & practice of oncology. 7th ed. (2004), Lippincott Williams & Wilkins, New York p. 2295
2. Liang R., Todd D., Chan T.K., et al. Treatment outcome and prognostic factors for primary nasal lymphoma. J Clin Oncol 13 (1995) 666-670
3. Chim C.S., Ma S.Y., Au W.Y., et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103 (2004) 216-221
4. Kwong Y.L. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 19 (2005) 2186-2194
5. Cheung M.M., Chan J.K., Lau W.H., et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 16 (1998) 70-77
6. Proulx G.M., Caudra-Garcia I., Ferry J., et al. Lymphoma of the nasal cavity and paranasal sinuses treatment and outcome of early stage disease. Am J Clin Oncol 26 (2003) 6-11
7. Au W.Y., Weisenburger D.D., Intragumtornchai T., et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 113 (2009) 3931-3937
8. Suzuki R., Takeuchi K., Oshima K., and Nakamura S. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol 26 (2008) 66-72
9. Spits H., Lanier L.L., and Phillips J.H. Development of human T and natural killer cells. Blood 85 (1995) 2654-2670
10. Liang X., and Graham D.K. Natural killer cell neoplasms. Cancer 112 (2008) 1425-1436
11. Ferry J.A., Sklar J., Zukerberg L.R., et al. Nasal lymphoma: a Clinicopathologic Study with immunophenotypic and genotypic analysis. Am J Surg Pathol 15 (1991) 268-279
12. International T Cell Lymphoma Project. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: pathology findings and clinical outcomes. J Clin Oncol 26 (2008) 1-10
13. Jaffe E.S. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 87 (1996) 1207-1210
14. Yong W., Zheng W., Zhu J., et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, effect of l-asparaginase based regimen, and prognostic factors. Hematol Oncol 24 (2006) 28-32
15. Jaccard A., Petit B., Girault S., et al. L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol Epub 20 (2008) 110-116
16. Nagafuji K., Fujisaki T., Arima F., and Ohshima K. l-Asparaginase induced durable remission of relapsed nasal NK/T-cell lymphoma after autologous peripheral blood stem cell transplantation. Int J Hematol 74 (2001) 447-450
17. Matsumoto Y., Nomura K., Kanda-Akano, et al. Successful treatment with Erwinia l-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 44 (2003) 879-882
18. Yong W., Zheng W., Zhu J., et al. l-Asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol Epub 88 (2008) 647-652
19. Yong W., Zheng W., Zhang Y., et al. l-Asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 78 (2003) 163-167
20. Kim W.S., Song S.Y., Ahn Y.C., et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer T-cell lymphoma?. Ann Oncol 12 (2001) 349-352
21. Li Y.X., Yao B., Jin J., et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 24 (2006) 181-189
22. Kim T.M., Lee S.Y., Jeon Y.K., et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol Epub 19 (2008) 1477-1484
23. Ribrag V., Hajj M.E., Janot F., et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 14 (2001) 1123-1126
24. You J.Y., Chi K.H., Yang M.H., et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 115 (2004) 618-625
25. Cheung M.M., Chan J.K., and Wong K.F. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Sem Hematol 40 (2003) 221-232
26. Yamaguchi M., Kita K., Miwa H., et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 76 (1995) 2351-2356
27. Wang B., Li X.Q., Ma X., et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-Cell lymphoma, nasal type. Am J Hematol 83 (2008) 795-799
28. Cabanillas F., Hagemeister F.B., Bodey G.P., and Freireich E.J. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 60 (1982) 693-697
29. Kim B.S., Kim D.W., Im S.A., et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann Oncol Epub 20 (2008) 121-128
30. Jaccard A., Gachard N., Coppo P., Morschhauser F., Galicier L., Ysebart L., et al. A prospective phase II trial of an l-asparaginase containing regimen in patients with refractory or relapsing extra nodal NK/T-cell lymphoma. Blood 112 (2008) A579
31. Yamaguchi M., Suzuki R., Kwong Y.L., Kim W.S., Hasegawa Y., Izutsu K., et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase and etoposide (SMILE) chemotherapy for advanced stage, relapsed or refractory extranodal natural killer (NK)/T cell lymphoma and leukemia. Cancer Sci 99 (2008) 1016-1020
32. Obama K., Tara M., and Niina K. L-asparaginase therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 78 (2003) 248-250
33. Ando M., Sugimoto K., Kitoh T., Sasaki M., Mukai K., Ando J., et al. Selective apoptosis of natural killer tumours by l-asparaginase. Br J Haematol 130 (2005) 860-868